Royalty Pharma Executive Files Insider Trading Transaction with SEC
1 report, 1 independent
Updated Oct 5
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royalty Pharma disclosed that its EVP, Marshall Urist, sold 4,126 shares of the company through a transaction that took place on October 5th. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at an average price of $57.10, totaling $235,594.60. This transaction was formally filed with the Securities & Exchange Commission.
From tickerreport.com
Why it matters
The filing details the required disclosure of executive stock sales for publicly traded companies. Such transactions are closely monitored by regulators and market participants.
From tickerreport.com
Who's involved
- Royalty PharmaBiopharmaceutical company subject to SEC disclosure requirements
- SECRegulatory body overseeing mandatory company filings
Keep exploring
The entities involved
-
Bank of America
American multinational banking and financial services corporation
-
Royalty Pharma
biopharmaceutical company based in New York City
Nothing else this week.
-
SEC
Slovak company
Related events
- Ligand Pharmaceuticals filed a transaction with the SEC, while Royal Bank of Canada lifted its target price, and the stock is listed on Nasdaq.
- Royalty Pharma is investing in drug makers and developers to diversify its portfolio in the biotech sector.
- Arcutis Biotherapeutics, Inc. disclosed an executive stock sale via a filing with the SEC on November 11, 2026.
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
- Data I/O Corporation filed acquisition documents with the SEC following significant stock purchases by major shareholders and institutional investors.